A unit dosage of an oral composition of an extract of Withania somnifera is disclosed. The extract of Withania somnifera includes total withanolides. The total withanolides includes withanolide glycosides and withanolide aglycones. The extract of Withania somnifera includes about 32% to about 38% by weight of the withanolide glycosides. Methods of preparing the extract of Withania somnifera are disclosed. Methods of treatment by administering the extract of Withania somnifera are disclosed.

A composition includes a cannabinoid agent in a range of 0.005% to 1%, a terpene agent in a range of 0.005% to 1%, and a co-fermented herbal complex in a range of 5% to 40%. The cannabinoid agent can include CBD, CBN, CBG, or a combination thereof. The composition can further include ashwagandha.

A composition includes a cannabinoid agent in a range of 0.005% to 1%, a terpene agent in a range of 0.005% to 1%, and a co-fermented herbal complex in a range of 5% to 40%. The cannabinoid agent can include CBD, CBN, CBG, or a combination thereof. The composition can further include ashwagandha.

In preferred embodiments the invention is directed to ocular compositions for the treatment of dry eye, methods for making such compositions, and suites comprising a plurality of different ocular compositions each having a defined composition. In preferred examples, the invention is directed to compositions comprising at least one natural oil, wherein a first member of the suite of compositions is effective in treating dry in in a first patient having a particular set of symptoms and a different second member of the suite of compositions is effective in treating dry in in a second patient having a different set of symptoms. The invention is also directed to methods of making and using the compositions, and to skin care compositions for use around the eye, such as the upper and lower eyelids having a lubricating, non-irritating base composition comprising at least one natural oil.

In preferred embodiments the invention is directed to ocular compositions for the treatment of dry eye, methods for making such compositions, and suites comprising a plurality of different ocular compositions each having a defined composition. In preferred examples, the invention is directed to compositions comprising at least one natural oil, wherein a first member of the suite of compositions is effective in treating dry in in a first patient having a particular set of symptoms and a different second member of the suite of compositions is effective in treating dry in in a second patient having a different set of symptoms. The invention is also directed to methods of making and using the compositions, and to skin care compositions for use around the eye, such as the upper and lower eyelids having a lubricating, non-irritating base composition comprising at least one natural oil.

The invention relates to an extract of Ashwagandha that exhibit enhanced bioactivity and bioavailability comprising of enriched withanolide glycosides and saponins; with negligible amount of alkaloids, withanolide aglycones and oligosaccharides. The extract as disclosed prepared from root, stems, leaves and whole plant of Ashwagandha further shows improved immunomodulatory activity, anti-inflammatory activity, anti stress activity, antidiabetic activity and sleep quality. The disclosure also provides a method of improving bioactivity of withanolide glycosides even at lower doses, by the administration of an enteric coated formulation of extract of Ashwagandha to humans. The enteric coating protects the composition from hydrolysis in the acidic environment of the stomach to release the withanolide glycoside in neutral/alkaline pH in gastrointestinal tract (GIT) thus enhancing the absorption. Further the process of preparation of the extract of Ashwagandha enriched with withanolide glycosides and saponins are disclosed along with various formulations.

The invention relates to an extract of Ashwagandha that exhibit enhanced bioactivity and bioavailability comprising of enriched withanolide glycosides and saponins; with negligible amount of alkaloids, withanolide aglycones and oligosaccharides. The extract as disclosed prepared from root, stems, leaves and whole plant of Ashwagandha further shows improved immunomodulatory activity, anti-inflammatory activity, anti stress activity, antidiabetic activity and sleep quality. The disclosure also provides a method of improving bioactivity of withanolide glycosides even at lower doses, by the administration of an enteric coated formulation of extract of Ashwagandha to humans. The enteric coating protects the composition from hydrolysis in the acidic environment of the stomach to release the withanolide glycoside in neutral/alkaline pH in gastrointestinal tract (GIT) thus enhancing the absorption. Further the process of preparation of the extract of Ashwagandha enriched with withanolide glycosides and saponins are disclosed along with various formulations.

Methods for treating or preventing viral infection-induced symptoms are disclosed. Methods for treating or preventing a viral infection are disclosed. Methods for treating or preventing mitochondrial dysfunction are disclosed. The viral infections include SARS-CoV-2, HIV, Influenza, and MERS. The methods include administering an emblica extract or a compound constituent of or having a similarity score of at least 95% with a compound constituent of an emblica extract, a fucus extract or a compound constituent of or having a similarity score of at least 95% with a compound constituent of a fucus extract, or a chebula extract or a compound constituent of or having a similarity score of at least 95% with a compound constituent of a chebula extract.

Methods for treating or preventing viral infection-induced symptoms are disclosed. Methods for treating or preventing a viral infection are disclosed. Methods for treating or preventing mitochondrial dysfunction are disclosed. The viral infections include SARS-CoV-2, HIV, Influenza, and MERS. The methods include administering an emblica extract or a compound constituent of or having a similarity score of at least 95% with a compound constituent of an emblica extract, a fucus extract or a compound constituent of or having a similarity score of at least 95% with a compound constituent of a fucus extract, or a chebula extract or a compound constituent of or having a similarity score of at least 95% with a compound constituent of a chebula extract.

A cream formulation or topical use made of a mixture of naturally occurring biologically active phytochemical compounds that possess a variety of beneficial animal and human health effects. An extract from an aqueous extraction process or other active ingredients could be used in the cream formulation. The present invention generally provides for the preparation of cream formulations containing active ingredients that contain individually, or in combination, an analgesic, natural product extracts, or a protein or proteins from the tripartite motif family of proteins (TRIM). The analgesic will provide mitigation of pain during the healing process.